Genotype and allele frequencies of the <i>IL6-174</i> (rs1800795) and <i>TNF-308</i> (rs1800629), (N = 125)

<p>Genotype and allele frequencies of the <i>IL6-174</i> (rs1800795) and <i>TNF-308</i> (rs1800629), (N = 125)</p

Demographics and clinical information of the patients (N = 125).

<p>Demographics and clinical information of the patients (N = 125).</p

A conceptual framework including determinants that might affect cognitive impairment in chemotherapy-treated breast cancer patients.

<p>This study was performed to evaluate the downstream effects of <i>TNF-308</i> and <i>IL6-174</i> polymorphisms on the circulating TNF-α and IL-6 levels, and the occurrence of chemotherapy-associated cognitive impairment.</p

Plasma IL-6 and TNF-α concentrations across the three time-points, after stratifying for the <i>IL6-174</i> and <i>TNF-308</i> genotypes (N = 125)

<p>Plasma IL-6 and TNF-α concentrations across the three time-points, after stratifying for the <i>IL6-174</i> and <i>TNF-308</i> genotypes (N = 125)</p

Impact of <i>TNF-α</i> (rs1800629) and <i>IL-6</i> (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients

<div><p>Objective</p><p>Expression of pro-inflammatory cytokines is influenced by single nucleotide polymorphisms (SNPs) in the promoter regions of the pro-inflammatory cytokine genes, and cytokines are associated with the occurrence of post-chemotherapy cognitive impairment. Hence, the aim of this study was to evaluate the associations between two common pro-inflammatory cytokine gene polymorphisms namely, <i>IL6-174</i> (rs1800795 G>C) and <i>TNF-308</i> (rs1800629 G>A), and chemotherapy-associated cognitive impairment (CACI) among Asian early-stage breast cancer patients. In addition, the differential effect of these SNPs on plasma IL-6 and TNF-α levels, and the associations of plasma IL-6 and TNF-α levels with CACI were also assessed.</p><p>Methods</p><p>Asian early-stage breast cancer patients (Stage I to III) receiving chemotherapy were prospectively recruited from two cancer centers in Singapore. Patients' cognitive function was longitudinally assessed using the validated FACT-Cog (ver. 3) and an objective computerized battery, Headminder™ at three-time points. Plasma IL-6 and TNF-α levels were analyzed using the multiplex immunoassay, and genotyping was performed using Sanger sequencing. Regression analyses and generalized estimating equation were utilized for statistical analysis.</p><p>Results</p><p>A total of 125 patients were included (mean age: 50.3; Chinese: 80.8%; post-menopausal: 48.0%; 68.0% received anthracycline-based chemotherapy). 36.8% patients experienced self-perceived cognitive impairment, detected in memory (32.8%) and attention (34.2%) domains. Patients with higher levels of anxiety (p<0.001) and insomnia (p = 0.003) also reported more self-perceived cognitive impairment. Higher plasma concentrations of IL-6 were associated with greater severity of self-perceived cognitive impairment (p = 0.001). Polymorphisms of cytokine genes were not associated with expression of plasma cytokines.</p><p>Conclusion</p><p>Present findings further contribute to the growing evidence that supports the role of the pro-inflammatory cytokine IL-6 in the occurrence of cognitive impairment post-chemotherapy. However, genetic polymorphism of these cytokines did not play a major role to the cytokine fluctuations as well as cognitive impairment in this cohort. With an increasing evidence to support the cytokine hypothesis, future studies should investigate the role of anti-inflammatory agents in mitigating the cognitive impairment associated with chemotherapy.</p></div

Plasma IL-6 and TNF-α concentrations across the three time-points, (N = 125).

<p>Plasma IL-6 and TNF-α concentrations across the three time-points, (N = 125).</p

Association of IL-6 concentrations with severity of self-perceived cognitive impairment (FACT-Cog) and the cognitive domains of Headminder™.

<p>Association of IL-6 concentrations with severity of self-perceived cognitive impairment (FACT-Cog) and the cognitive domains of Headminder™.</p